(2S,4R)-1-((S)-2-(3-(2-(5-(4-(4-cyano-2-(trifluoromethyl)benzyl)-3-methoxybenzylidene)-2,4-dioxothiazolidin-3-yl)ethoxy)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide

ID: ALA5174819

Chembl Id: CHEMBL5174819

PubChem CID: 168272490

Max Phase: Preclinical

Molecular Formula: C47H49F3N6O8S2

Molecular Weight: 947.07

Associated Items:

Names and Identifiers

Canonical SMILES:  COc1cc(/C=C2\SC(=O)N(CCOCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCc3ccc(-c4scnc4C)cc3)C(C)(C)C)C2=O)ccc1Cc1ccc(C#N)cc1C(F)(F)F

Standard InChI:  InChI=1S/C47H49F3N6O8S2/c1-27-40(65-26-53-27)31-10-6-28(7-11-31)24-52-42(59)36-22-34(57)25-56(36)44(61)41(46(2,3)4)54-39(58)14-16-64-17-15-55-43(60)38(66-45(55)62)20-29-8-13-33(37(19-29)63-5)21-32-12-9-30(23-51)18-35(32)47(48,49)50/h6-13,18-20,26,34,36,41,57H,14-17,21-22,24-25H2,1-5H3,(H,52,59)(H,54,58)/b38-20-/t34-,36+,41-/m1/s1

Standard InChI Key:  KNVMDVDLBWIQNQ-UGZDYVQHSA-N

Alternative Forms

  1. Parent:

    ALA5174819

    ---

Associated Targets(Human)

ESRRA Tchem von Hippel-Lindau disease tumor suppressor/Steroid hormone receptor ERR1 (46 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 947.07Molecular Weight (Monoisotopic): 946.3005AlogP: 6.86#Rotatable Bonds: 16
Polar Surface Area: 191.26Molecular Species: NEUTRALHBA: 12HBD: 3
#RO5 Violations: 3HBA (Lipinski): 14HBD (Lipinski): 3#RO5 Violations (Lipinski): 3
CX Acidic pKa: 12.25CX Basic pKa: 2.65CX LogP: 5.30CX LogD: 5.30
Aromatic Rings: 4Heavy Atoms: 66QED Weighted: 0.08Np Likeness Score: -1.05

References

1. Wang C, Zhang Y, Wang J, Xing D..  (2022)  VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives.,  227  [PMID:34656901] [10.1016/j.ejmech.2021.113906]

Source